Video

Safety, efficacy of KPI-121 0.25% for DED treatment

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of dry eye disease in patients enrolled in four trials.

See more AAO coverage

Related Videos
Image credit: ©Ophthalmology Times
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
© 2025 MJH Life Sciences

All rights reserved.